All Posts Tagged With: "ALKS"
(ALKS) Risk-Reward Balanced at Alkermes
We are maintaining a Neutral rating on Alkermes (ALKS) with a target price of $18.00.
Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results. This...
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a...
(AMLN) Amylin Pharmaceuticals Posts Lower Loss
Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher...
(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the...
(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs
Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite...
(NVO) Novo Nordisk Presents Late Stage Degludec Data
Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low...
(ALKS) Alkermes Presents Encouraging Data
Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32). ALKS 9070 is a once-monthly injectable extended release version...
(NVO) Novo Nordisk Presents Diabetes Study Data
Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human Glucagon-Like...
(ALKS) Alkermes Evenly Poised
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00.
Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery...
(AMLN) Amylin Pharmaceuticals, Partners Eli Lilly and Alkermes Learn Bydureon Gains EU Approval
Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (
22Jun2011 | vitalstocks | 0 comments | Continued(ALKS) Stock Market News for May 10, 2011 – Market News
After suffering a slump last week, commodities made a strong comeback yesterday and lifted the benchmarks higher. Energy shares joined in on the uptrend as crude prices once again rose above $100 per barrel. Meanwhile fresh worries about Greece’s credit ratings partially...
(ALKS) Alkermesto Buy Elan Unit for $960 Million
Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The...
(AMLN) Amylin Pharmaceuticals Reports Earnings Loss In-Line with Estimates
Amylin Pharmaceuticals (AMLN) reported a net loss of 24 cents per share in the first quarter of 2011, in line with the Zacks Consensus Estimate and 3 cents below the year-ago loss of 27 cents. Despite a decline...
(AMLN) Amylin Pharmaceuticals, Eli Lilly, and Alkermes Get Positive Opinion for Bydureon
Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (
18Apr2011 | vitalstocks | 0 comments | Continued(ALKS) Company News for April 18, 2011 – Corporate Summary
• Chesapeake Energy Corp’s. (NYSE:CHK) share prices gained 0.25% after it announced plans to buy Bronco Drilling Co. (NASDAQ:BRNC) for $11 a share. The purchase...
(AMLN) Amylin Pharmaceuticals Analyst Reports Neutral on Shares
We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). The company reported a net loss of $0.94 per share in 2010, narrower than the Zacks Consensus Estimate of $1.26 and...
(AMLN) Amylin Pharmaceuticals Releases Disappointing Data
Shares of Amylin Pharmaceuticals, Inc. (AMLN) lost more than 25% when the company released disappointing data on Bydureon (exenatide once-weekly) from a head-to-head study. Bydureon failed to achieve its...
(AMLN) Amylin Pharmaceuticals Analyst Maintains Neutral
We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). Amylin reported a net loss of $0.31 per share in the third quarter of 2010, three cents below the Zacks Consensus...
(ALKS) Alkermes 2010 Second Quarter Revenues Rise – View Lowered
Alkermes Inc.’s (ALKS) second quarter fiscal 2011 net loss (excluding special items) of 6 cents per share compared unfavorably with the year-ago loss of 5 cents per share. The Zacks Consensus Estimate was...
(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
(AMLN) Amylin Pharmaceuticals Reports Wider Loss
Amylin Pharmaceuticals (AMLN) reported a net loss of 31 cents per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year-earlier loss of 19 cents. Lower...
(ALKS) Alkermes’ Vivitrol Earns US Food and Drug Administration Clearance
Alkermes Inc. (ALKS) received a boost when the US Food and Drug Administration (FDA) cleared its drug Vivitrol (naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid...
(ALKS) Alkermes Earnings Report Shows Revenues Dipped
Alkermes Inc.’s (ALKS) first-quarter fiscal 2011 net loss of 14 cents per share compared unfavorably with the year-ago loss of 2 cents per share. The Zacks Consensus Estimate was a loss of 14 cents per...
(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect...
(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect...
(ALKS) Alkermes, Amylin Pharmaceuticals, and Eli Lilly See Encouraging Data on Diabetes Candidate Bydureon
Recently Alkermes Inc. (ALKS), Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (
29Jun2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes’ Quarterly Earnings Report Shows Revenue Dip
Alkermes Inc. (ALKS) reported a fourth quarter fiscal 2010 net loss of 12 cents per share (excluding special items but including stock-based compensation) compared with a loss of 13 cents per share in the...
(ALKS) Alkermes Files New Drug Application For Vivitrol Expansion
Recently Alkermes, Inc. (ALKS) submitted a supplemental New Drug Application (sNDA) for Vivitrol (naltrexone for extended-release injectable suspension) to the US Food and Drug Administration (FDA) for treating...
(ALKS) Alkermes Drug Pipeline Advances
Recently, Alkermes Inc. (ALKS) initiated a multidose early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist, which has the potential to block...
(AMLN) Amylin Pharmaceuticals’ Drug Approval Delayed
The US Food and Drug Administration (FDA) recently issued a complete response letter delaying the approval of Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly and Co. (
16Mar2010 | vitalstocks | 0 comments | Continued